BioPlus Acquisition Corp. (NASDAQ:BIOS) shares traded -0.10% lower at $10.40 on Wall Street last session.
BIOS stock price is now 1.19% away from the 50-day moving average and 3.35% away from the 200-day moving average. The market capitalization of the company currently stands at $304.82M.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
A total of 3.73% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in BIOS stock. A new stake in BioPlus Acquisition Corp. shares was purchased by CALAMOS ADVISORS LLC during the first quarter worth $10,400,000. SPRING CREEK CAPITAL LLC invested $5,200,000 in shares of BIOS during the first quarter. In the first quarter, LMR PARTNERS LLP acquired a new stake in BioPlus Acquisition Corp. valued at approximately $3,900,000. WESTCHESTER CAPITAL MANAGEMENT, LLC acquired a new stake in BIOS for approximately $1,708,000. EXOS TFP HOLDINGS LLC purchased a new stake in BIOS valued at around $650,000 in the second quarter. In total, there are 72 active investors with 85.80% ownership of the company’s stock.
BioPlus Acquisition Corp. (NASDAQ: BIOS) opened at $10.41 on Wednesday. During the past 12 months, BioPlus Acquisition Corp. has had a low of $9.85 and a high of $10.43. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 2.20, and a quick ratio of 2.20. The fifty day moving average price for BIOS is $10.32 and a two-hundred day moving average price translates $10.11 for the stock.
The latest earnings results from BioPlus Acquisition Corp. (NASDAQ: BIOS) was released for Sep, 2022. For the current quarter, analysts expect BIOS to generate $684.51M in revenue.
BioPlus Acquisition Corp.(BIOS) Company Profile
BioPlus Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses in the life sciences industry. The company was incorporated in 2021 and is based in New York, New York.
Leave a Reply